Summary
Deprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients.
Phenylethylamine and amphetamine have been investigated using a gas chromatographie technique.
This is a preview of subscription content, log in via an institution to check access.
References
Antelman, S. M., Edwards, D. J., Lin, M. Phenylethylamine: evidence for a direct postsynaptic dopamine-repector stimulating action. Brain Res.127, 317 (1977).
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W. The potentiation of the Anti-Akinetic Effect after L-Dopa Treatment by an Inhibitor of MAO-B, Deprenil. J. Neural Transm.36, 303–326 (1975).
Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A. J., Phuapradit, P., Shaw, K. M., Stern, G. M., Kumar, P. Deprenyl administration in man: A selective Monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacol.57, 33–38 (1978).
Glover, V., Sandler, M., Owen, F., Riley, G. J. Dopamine is a monoamine oxidase B substrate in man. Nature (Lond.)265, 80–81 (1977).
Innes, I. R., Nickerson, M.: Norepinephrine, epinephrine and the sympathomimetic amines. In: The Pharmacological Basis of Therapeutics (Goodman, L. S., Gilman, A., eds.), pp. 477–513. New York. 1977.
Jackson, D. M. β-phenylethylamine and Locomotor activity in mice. Arzneim.-Forsch.25, 622–626 (1975).
Knoll, J. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine Oxidase and its Inhibitors (Wolstenholme, G. E. W., Knight, J., eds.), pp. 135–161. Amsterdam: Elsevier. 1976.
Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B. H. Deprenyl in Parkinson's disease. Lancetii, 791–796 (1977).
Moore, K. E. The actions of amphetamine on neurotransmitters. Biol. Psychiat.12, 451–462 (1977).
Nakajima, T., Kakimoto, Y., Sano, I. Formation ofβ-phenylethylamine in mammalian tissue and its effect on motor activity. J. Pharmacol. exp. Ther.143, 319–325 (1964).
Parkes, J. D., Tarsy, D., Marsden, C. D., Bovill, K. T., Phipps, J. A., Rose, P., Asselman, P. Amphetamines in the treatment of Parkinson's disease. J. Neurol. Neurosurgery Psychiat.38, 232–237 (1975).
Philips, S. R. β-phenylethylamine: a metabolically and pharmacologically active amine. In: Noncatecholic Phenylethylamines, I (Mosnaim, A. D., Wolf, M. E., eds.), pp. 113–138. New York: Dekker. 1978.
Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J., Stern, G. M.: Deprenyl is metabolized to methamphetamine and amphetamine in man. (In press.)
Reynolds, G. P., Sandler, M., Hardy, J., Bradford, H.: Determination and distribution of 2-phenylethylamine in sheep brain. (In preparation.)
Riederer, P., Youdim, M. B. H., Birkmayer, W., Jellinger, K. Monoamine oxidase activity during (-)deprenyl therapy: Human brain post mortem studies. In: Adv. Biochem. Pharmacol. 19 (Roberts, P. J., Iversen, L. L., eds.), pp. 377–382. New York: Raven Press. 1978.
Yang, H.-Y. T., Neff, N. H. β-phenylethylamine: a specifie substrate for type B monoamine oxidase of brain. J. Pharmacol. Exp. Ther.187, 365–371 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reynolds, G.P., Riederer, P., Sandler, M. et al. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural Transmission 43, 271–277 (1978). https://doi.org/10.1007/BF01246964
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01246964